Similar articles

• Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.

  Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA. Tijink BM, et al. J Nucl Med. 2006 Jul;47(7):1127-35. J Nucl Med. 2006. PMID: 16818947
• Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation.

  Jain M, Venkatraman G, Batra SK. Jain M, et al. Clin Cancer Res. 2007 Mar 1;13(5):1374-82. doi: 10.1158/1078-0432.CCR-06-2436. Epub 2007 Feb 19. Clin Cancer Res. 2007. PMID: 17309914 Review.
• Vaccines targeting tumor vasculature: a new approach for cancer immunotherapy.

  Croix BS. Croix BS. Cytotherapy. 2007;9(1):1-3. doi: 10.1080/14653240601118444. Cytotherapy. 2007. PMID: 17354097 No abstract available.
• Radioimmunotherapy. Progress, potential and problems.

  Mather SJ, Britton KE. Mather SJ, et al. Q J Nucl Med Mol Imaging. 2004 Dec;48(4):248-50. Q J Nucl Med Mol Imaging. 2004. PMID: 15640787 No abstract available.
• Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma.

  Buchegger F, Press OW, Delaloye AB, Ketterer N. Buchegger F, et al. Oncologist. 2008 Jun;13(6):657-67. doi: 10.1634/theoncologist.2008-0020. Oncologist. 2008. PMID: 18586921 Review.